| 40.0001 -0.04 (-0.1%) | 09-20 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Calliditas Therapeutics AB (publ) operates as a clinical-stage biopharmaceutical entity, committed to identifying, advancing, and commercializing therapeutic products. Its primary focus lies in developing treatments for rare (orphan) conditions, with a particular emphasis on disorders impacting the renal and hepatic systems. The company markets Nefecon, an orally administered formulation of budesonide, which functions as an immunosuppressive agent designed to address immunoglobulin A nephropathy, an autoimmune kidney disease. Its flagship investigational product is Setanaxib, a NOX inhibitor. Setanaxib is currently undergoing Phase 2b/3 clinical trials for primary biliary cholangitis. Furthermore, it is being evaluated in Phase 2 studies for various other indications, including squamous cell carcinoma of the head and neck, idiopathic pulmonary fibrosis, and type 1 diabetic kidney disease. Calliditas's pipeline also includes Budenofalk 3 mg oral capsules, which are under development for the treatment of autoimmune hepatitis. The company was established in 2004 and has its corporate headquarters located in Stockholm, Sweden.
Thu, 24 Apr 2025
Calliditas Therapeutics Ab (CALT) Stock Price, News & Analysis - Stock Titan
Wed, 15 Dec 2021
FDA grants Calliditas Therapeutics Accelerated Approval of Tarpeyo - PharmaLive
Mon, 03 Aug 2020
Calliditas Therapeutics Ab (CALT) Stock News - Stock Titan
Tue, 30 Jun 2020
Calliditas Therapeutics AB (publ) (CALT) Stock Price, News & Analysis $CALT - MarketBeat
Mon, 27 Apr 2020
Top Organogenesis (ORGO) Competitors 2026 - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|